Researchers Get Ready For NIH Reforms

As the agency overhauls its peer-review system, scientists assess the potential consequences. The peer-review system at the National Institutes of Health is in the midst of a critical series of reforms that will alter the way study sections judge and score grant applications. For the first time, reviewers will be required to consider five explicit criteria in judging grants, and one criterion will have the effect of placing a premium on innovative science. But NIH director Harold Varmus reject

Written byRobert Finn
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

As the agency overhauls its peer-review system, scientists assess the potential consequences. The peer-review system at the National Institutes of Health is in the midst of a critical series of reforms that will alter the way study sections judge and score grant applications. For the first time, reviewers will be required to consider five explicit criteria in judging grants, and one criterion will have the effect of placing a premium on innovative science. But NIH director Harold Varmus rejected a controversial recommendation from an internal committee calling for each criterion to be scored separately, so reviewers will continue to assign a single global score to applications. Additional changes, planned for the next year or two, involve reorganizations of study sections and possibly more changes in scoring. Despite praise for the changes from most quarters, some researchers are concerned about the consequences of the reforms and the details of how they ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies